JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB180707

Anti-UGT1A9 antibody

4

(2 Reviews)

|

(2 Publications)

Rabbit Polyclonal UGT1A9 antibody. Suitable for WB, ICC/IF and reacts with Human, Mouse samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 1-250.

View Alternative Names

GNT1, UGT1, UGT1A9, UDP-glucuronosyltransferase 1A9, UDP-glucuronosyltransferase 1-9, UDP-glucuronosyltransferase 1-I, lugP4, UDPGT 1-9, UGT1*9, UGT1-09, UGT1.9, UGT-1I, UGT1I

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-UGT1A9 antibody (AB180707)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-UGT1A9 antibody (AB180707)

Immunocytochemistry/Immunofluorescence analysis of MCF7 cells using ab180707. Blue DAPI for nuclear staining.

Western blot - Anti-UGT1A9 antibody (AB180707)
  • WB

Supplier Data

Western blot - Anti-UGT1A9 antibody (AB180707)

All lanes:

Western blot - Anti-UGT1A9 antibody (ab180707) at 1/500 dilution

Lane 1:

A549 cell extract

Lane 2:

HT29 cell extract

Lane 3:

MCF7 cell extract

Lane 4:

HeLa cell extract

Lane 5:

Mouse liver cell extract

Predicted band size: 60 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human

Applications

ICC/IF, WB

applications

Immunogen

Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 1-250. The exact immunogen used to generate this antibody is proprietary information.

O60656

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/2000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/2000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.3 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UGT1A9 also known as UDP-glucuronosyltransferase 1-9 mechanistically catalyzes the glucuronidation of a variety of substrates including pharmaceuticals endogenous compounds and xenobiotics. It belongs to the UGT1A family with an approximate mass of 56 kDa. UGT1A9 is mainly expressed in the liver but it also shows expression in other tissues like the kidney and the small intestine. The enzyme plays an important role in increasing the solubility of drugs aiding their excretion from the body.
Biological function summary

UGT1A9 is involved in phase II metabolism contributing to the detoxification processes within the liver. It functions by adding glucuronic acid to lipophilic molecules making them more water-soluble. This glucuronidation process is essential for the clearance of bilirubin steroids and various drugs. UGT1A9 exists as a part of a larger enzyme complex that includes other UGT1A family members. Together these enzymes regulate action and metabolism of diverse physiological substances.

Pathways

The UGT1A9 enzyme contributes significantly to the glucuronidation pathway and assists in the drug metabolism pathway. It shares functional relationships with other UGT1A enzymes like UGT1A1 particularly in the metabolism of bilirubin. In the drug metabolism pathway UGT1A9 interacts with cytochrome P450 enzymes playing an important role in the reduction of drug toxicity and facilitation of drug clearance.

UGT1A9 has been linked to Gilbert's syndrome and drug-induced hepatotoxicity. Mutations or polymorphisms in the UGT1A9 gene can lead to impaired ability of the enzyme to glucuronidate bilirubin potentially contributing to hyperbilirubinemia in Gilbert's syndrome. UGT1A9 also interacts with proteins such as UGT1A1 in the context of drug-induced liver injury affecting the metabolism of certain therapeutic drugs leading to potential toxic buildup.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Isoform 1. UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed : 12181437, PubMed : 15470161, PubMed : 15472229, PubMed : 18004212, PubMed : 18052087, PubMed : 18674515, PubMed : 19545173). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed : 12181437, PubMed : 18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol and estrone (PubMed : 15472229). Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed : 18052087, PubMed : 19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II (PubMed : 18674515). Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed : 12181437, PubMed : 20610558). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed : 15470161, PubMed : 18004212).. Isoform 2. Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
See full target information UDP-glucuronosyltransferase 1A9

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 15:28552 PubMed40764617

2025

Temporal changes of hepatic drug-metabolizing enzymes mediated by hepatic ischemia-reperfusion injury and the protective effect of Oridonin.

Applications

Unspecified application

Species

Unspecified reactive species

Tanwei Gu,Fahong Dai,Meiqun Cai,Xi Zhang,Danni Xie,Huanguo Jiang,Lingmin Tian,Liyan Yan,Wenxun Lan,Haitao Lv,Lan Tang,Hong Li,Zhaoguo Liu

Clinical colorectal cancer 17:e45-e48 PubMed29054804

2017

Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver.

Applications

IHC-P

Species

Unspecified reactive species

Junichi Okada,Shunichi Matsumoto,Kyoichi Kaira,Tsugumichi Saito,Eijiro Yamada,Hideaki Yokoo,Ryuji Katoh,Motoyasu Kusano,Shuichi Okada,Masanobu Yamada
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com